Literature DB >> 954011

Nitrosourea pharmacodynamics in relation to the central nervous system.

M D Walker, J Hilton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954011

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  8 in total

1.  Value of serial stereotactic biopsies and impedance monitoring in the treatment of deep brain tumours.

Authors:  G Broggi; A Franzini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-05       Impact factor: 10.154

2.  Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models.

Authors:  Shin-ichiro Sugiyama; Yoji Yamashita; Toshio Kikuchi; Ryuta Saito; Toshihiro Kumabe; Teiji Tominaga
Journal:  J Neurooncol       Date:  2006-09-20       Impact factor: 4.130

Review 3.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Clinical pharmacokinetics of oral CCNU (lomustine).

Authors:  F Y Lee; P Workman; J T Roberts; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 5.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

6.  Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

7.  Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.

Authors:  Defeng Zhao; Liren Qian; Jianliang Shen; Xiaopeng Liu; Ke Mei; Jian Cen; Yaming Wang; Congyong Li; Yuanyuan Ma
Journal:  J Cell Mol Med       Date:  2014-03-13       Impact factor: 5.310

8.  Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.

Authors:  Liren Qian; Chunhui Zhou; Jianliang Shen; Jian Cen; Wenjie Yin
Journal:  Oncotarget       Date:  2016-05-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.